ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Çüº°, Á¦Ç°º°, ¼­ºñ½ºº°, ±â¼úº°, ¿ëµµº°, µð¹ÙÀ̽ºº°, ÃÖÁ¾ »ç¿ëÀÚº°, ÄÄÆ÷³ÍÆ®º°, ±â´Éº°, Àü°³º°
Healthcare Bioconvergence Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, Device, End User, Component, Functionality, Deployment
»óǰÄÚµå : 1813535
¸®¼­Ä¡»ç : Global Insight Services
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 347 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,731,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,148,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,565,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀº 2024³â 1,454¾ï ´Þ·¯¿¡¼­ 2034³â¿¡´Â 2,714¾ï ´Þ·¯·Î È®´ëµÇ¾î CAGR ¾à 6.4%¸¦ ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå¿¡´Â ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» Çõ½ÅÇϱâ À§ÇÑ »ý¹°ÇÐ, ¿£Áö´Ï¾î¸µ, µðÁöÅÐ ±â¼úÀÇ ÅëÇÕÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ÇÐÁ¦ °£ Á¢±Ù¹ýÀº »ý¸í°øÇÐ, µ¥ÀÌÅÍ ºÐ¼®, ÀÇ·á±â±â¸¦ Ȱ¿ëÇÏ¿© Áø´Ü, Ä¡·á ¹× ȯÀÚ °ü¸®¸¦ °­È­ÇÕ´Ï´Ù. Á¤¹Ð ÀÇ·á¿Í °³ÀÎÈ­ ÇコÄɾ º¸±ÞµÊ¿¡ µû¶ó À¯ÀüüÇÐ, ÀΰøÁö´É, ¿þ¾î·¯ºí ±â¼úÀÇ Áøº¸°¡ ½ÃÀåÀ» °ßÀÎÇØ Çõ½ÅÀûÀÎ Ä¡·á ¹× Áø´Ü ±â¼úÀÌ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀº »ý¸í°øÇÐ, Á¤º¸ ±â¼ú, ¿£Áö´Ï¾î¸µÀÇ ÅëÇÕÀ¸·Î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦¿Í ¼¼Æ÷ Ä¡·á´Â Çõ½ÅÀ» ÃßÁøÇÏ°í °³ÀÎÈ­ Ä¡·á ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ºÐÀÚ Áø´ÜÇаú À̹Ì¡±â¼úÀÇ Áøº¸·Î Áúº´ÀÇ Á¶±â ¹ß°ß°ú Á¤¹Ð ÀÇ·á°¡ °­È­µÇ°í Áø´ÜÇÐÀÌ ¹ßÀüÇÕ´Ï´Ù. Ä¡·áÁ¦´Â À¯ÀüÀÚ ÆíÁý°ú Àç»ý ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñ È®´ë·Î ¸¸¼º ÁúȯÀ̳ª Èñ±Í Áúȯ¿¡¼­ÀÇ º¯È­°¡ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. Áø´Ü ºÐ¾ß¿¡¼­´Â AI¸¦ Ȱ¿ëÇÑ Áø´Ü Åø°ú ¿þ¾î·¯ºí °Ç°­ ¸ð´ÏÅ͸µ ±â±âÀÇ µîÀåÀÌ ±â¼¼¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ½Ç½Ã°£ °Ç°­ µ¥ÀÌÅÍ ºÐ¼®°ú »çÀü Ȱ¼º °Ç°­ °ü¸®°¡ ÃËÁøµË´Ï´Ù. ¹ÙÀÌ¿À¸Å´ºÆÑó¸µ ÇÏÀ§ ºÎ¹®µµ Å« Áøº¸¸¦ ÀÌ·ç°í ÀÖÀ¸¸ç, ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú°ú 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ±â¼úÀÌ »ý»ê È¿À²°ú È®À强À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ¸ÂÃãÇü ÀÇ·á¿Í ¿¹¹æ ÀǷḦ Á¡Á¡ ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀº ±â¼ú Çõ½Å, ¿¬°è, ÅõÀÚ¸¦ À§ÇÑ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÏ¿© Áö¼Ó °¡´ÉÇÑ ¼ºÀå°ú ȯÀÚÀÇ ¿¹ÈÄ °³¼±À» º¸ÀåÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­
À¯Çü Ä¡·áÁ¦, Áø´ÜÁ¦, ¿¹¹æ, ÀçȰ
Á¦Ç° ¹ÙÀÌ¿À¸ÓƼ¸®¾ó, ¹ÙÀÌ¿ÀÀÏ·ºÆ®·Î´Ð½º, ¹ÙÀÌ¿ÀÆ÷Åä´Ð½º, ¹ÙÀÌ¿À¼¾¼­, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Åø
¼­ºñ½º ÄÁ¼³ÆÃ, ±¸Çö, Áö¿ø ¹× À¯Áöº¸¼ö, °ü¸® ¼­ºñ½º, Æ®·¹ÀÌ´× ¹× ±³À°
±â¼ú ³ª³ë±â¼ú, À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ÇÕ¼º»ý¹°ÇÐ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º, Á¶Á÷°øÇÐ
¿ëµµ ½Å¾à, ÀÓ»ó½ÃÇè, ¸ÂÃãÇü ÀÇ·á, ÀÇ·á À̹Ì¡, Àç»ý ÀÇ·á
ÀåÄ¡ ¿þ¾î·¯ºí µð¹ÙÀ̽º, ÀÓÇöõÆ® µð¹ÙÀ̽º, Áø´Ü µð¹ÙÀ̽º, ¸ð´ÏÅ͸µ µð¹ÙÀ̽º, Ä¡·á µð¹ÙÀ̽º
ÃÖÁ¾ »ç¿ëÀÚ º´¿ø, ¿¬±¸±â°ü, Á¦¾àȸ»ç, »ý¸í°øÇÐȸ»ç, Çмú±â°ü
±¸¼º¿ä¼Ò ¼ÒÇÁÆ®¿þ¾î, Çϵå¿þ¾î, Ç÷§Æû
±â´É µ¥ÀÌÅÍ ºÐ¼®, ½Ã¹Ä·¹À̼Ç, ¸ðµ¨¸µ, ½Ã°¢È­
¹èÆ÷ On-Premise, Ŭ¶ó¿ìµå ±â¹Ý, ÇÏÀ̺긮µå

½ÃÀå ÇöȲ

ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀº ½ÃÀå Á¡À¯À², °¡°Ý Àü·«, ½ÅÁ¦Ç° ÅõÀÔ¿¡¼­ ¿ªµ¿ÀûÀÎ º¯È­¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »ý¹°Çаú °øÇÐÀ» À¶ÇÕ½ÃŲ ÃÖ÷´Ü ±â¼úÀ» µµÀÔÇÔÀ¸·Î½á º¸´Ù Å« Á¡À¯À²À» ȹµæÇÏ·Á´Â Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀ» äÅÃÇÏ´Â ±â¾÷ÀÌ ´Ã°í ÀÖ½À´Ï´Ù. °¡°Ý °æÀïÀº ½Å±Ô ÁøÃâ ±â¾÷ÀÇ À¯ÀÔ°ú ±âÁ¸ ±â¼úÀÇ ²÷ÀÓ¾ø´Â ÁøÈ­¿¡ ÀÇÇØ Áö¼ÓµÇ°í ÀÖ½À´Ï´Ù. ÀÌ °æÀï ±¸µµ´Â Á¦Ç° ¶óÀξ÷ÀÇ Ãæ½ÇÈ­¿Í ½ÃÀå µµ´Þ ¹üÀ§ÀÇ È®´ë¸¦ ¸ñÇ¥·Î ÇÏ´Â Àü·«Àû Á¦ÈÞ¿Í ÆÄÆ®³Ê½Ê¿¡ ÀÇÇØ ´õ¿í °ÝÈ­µÇ°í ÀÖ½À´Ï´Ù. ±â¼ú Áøº¸ÀÇ ±Þ¼ÓÇÑ ¼Óµµ¿Í º¹ÀâÇÑ °Ç°­ °ü¸® ¹®Á¦¿¡ ´ëÇÑ ³ë·Â¿¡ ´ëÇÑ ¾÷°èÀÇ Çå½ÅÀ» ¹Ý¿µÇÏ¿© ½ÅÁ¦Ç° Ãâ½Ã°¡ ÀÚÁÖ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °æÀï º¥Ä¡¸¶Å·¿¡ µû¸£¸é ¼±µÎ Á¦¾à ±â¾÷¿¡¼­ ¹ÎøÇÑ »ý¸í°øÇÐ ½ÅÈï ±â¾÷¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ±â¾÷ÀÌ Á¸ÀçÇÑ´Ù´Â °ÍÀÌ ¹àÇôÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ¹ÙÀÌ¿ÀÄÁ¹öÀü½º¸¦ Ȱ¿ëÇÏ¿© °æÀï·ÂÀ» ³ôÀ̰í, ¸ÂÃãÇü ÀÇ·á ¹× Á¤¹Ð Ä¡·á¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ »óȲÀÇ ¿µÇâÀº ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¾ö°ÝÇÑ ÁöħÀÌ ½ÃÀå »óȲÀ» Çü¼ºÇÏ°í ¾ÈÀü°ú È¿°ú¸¦ º¸ÀåÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ƯÈ÷ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ±â¼ú Çõ½ÅÀÇ ÃÖÀü¼±¿¡ ÀÖ´Â ºÏ¹Ì¿Í À¯·´¿¡¼­ °Å¾×ÀÇ R&D ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ¾÷°è°¡ ¹ßÀüÇÔ¿¡ µû¶ó °Ç°­ °ü¸®¿Í ±â¼úÀÇ À¶ÇÕÀÌ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÌÇØ°ü°èÀÚ¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä µ¿Çâ°ú ÃËÁø ¿äÀÎ

ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀº ±â¼úÀÇ Áøº¸¿Í ÇÐÁ¦ °£ Çù¾÷À» ÅëÇØ ±Þ¼ÓÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÁÖ¿ä µ¿ÇâÀº »ý¹°Çаú ¿£Áö´Ï¾î¸µÀÇ À¶ÇÕÀ¸·Î Áø´Ü°ú Ä¡·áÀÇ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀΰøÁö´É°ú »ý¸í°øÇÐÀÇ À¶ÇÕÀº °³ÀÎÈ­µÈ ÀÇ·á¿Í Á¤¹Ð °Ç°­ °ü¸®¸¦ ÃËÁøÇÏ¿© ȯÀÚÀÇ ¿¹ÈÄ¿Í Ä¡·á È¿°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ µ¿ÇâÀº º¥Ã³ ijÇÇÅ»·ÎºÎÅÍ °Å¾×À» ÅõÀÚ¹Þ´Â ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÅÈï ±â¾÷ÀÇ »ó½ÂÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½ÅÈï ±â¾÷µéÀº ½Å¾à°ú °³¹ßÀÇ »õ·Î¿î Á¢±Ù¹ýÀ» °³Ã´Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº ¶ÇÇÑ ¹ÙÀÌ¿ÀÄÁ¹öÀü½º Çõ½ÅÀ» Áö¿øÇÏ´Â ¿òÁ÷ÀÓÀ» °­È­Çϰí ÀÖÀ¸¸ç, ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­Çϱâ À§ÇØ ½ÂÀÎ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº ½ÃÀå È®´ëÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â ¼ö¼ú¿¡ ´ëÇÑ ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ±â¼úÀÇ Ã¤¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® »ýüÀç·á¿Í ¹ÙÀÌ¿ÀÀÏ·ºÆ®·Î´Ð½ºÀÇ °³¹ß¿¡´Â ºñÁî´Ï½º ±âȸ°¡ dzºÎÇϰí, ±âÁ¸ ÇコÄÉ¾î ÆÐ·¯´ÙÀÓÀ» º¯È­½ÃŰ´Â Å¼¼°¡ °®ÃçÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿Çâ°ú ÃËÁø ¿äÀÎÀ» Ȱ¿ëÇÏ´Â ±â¾÷Àº ±Þ¼ºÀåÇÏ´Â ½ÃÀåÀÇ ÀáÀç·ÂÀ» Ȱ¿ëÇÏ´Â µ¥ À¯¸®ÇÑ ÀÔÀå¿¡ ÀÖ½À´Ï´Ù.

¾ïÁ¦ ¿äÀΰú °úÁ¦

ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀº ¿©·¯ ÀÓ¹ÚÇÑ ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀΰú ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. °¡Àå Å« ¹®Á¦´Â ´Ù¾çÇÑ ±â¼úÀ» ÅëÇÕÇÏ´Â º¹À⼺À̸ç, ÀÌ´Â ¿øÈ°ÇÑ ÄÁ¹öÀü½º¿Í ºñÁî´Ï½º È¿À²¼ºÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺Àº Á¾Á¾ ºñ¿ë Áõ°¡¿Í °³¹ß ±â°£ÀÇ Àå±âÈ­¸¦ ÃÊ·¡ÇÏ¿© Áß¼Ò±â¾÷ÀÇ ½ÃÀå ÁøÀÔÀ» ÀúÇØÇÕ´Ï´Ù. ±ÔÁ¦ Àå¾Ö¹°Àº ½ÃÀå ¿ªÇÐÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µì´Ï´Ù. ¾ö°ÝÇÑ ÄÄÇöóÀ̾𽺠¿ä±¸ »çÇ×ÀÌ Á¦Ç° ½ÂÀÎ ¹× ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ãų ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦´Â ¾ÈÀüÀ» º¸ÀåÇÏ´Â µ¥ ÇʼöÀûÀÌÁö¸¸ ±â¼ú Çõ½ÅÀ» ¹æÇØÇϰí ÅõÀÚ ÀÇ¿åÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á´Â ¶Ç ´Ù¸¥ Å« µµÀüÀÔ´Ï´Ù. ¹ÙÀÌ¿ÀÄÁ¹öÀü½º´Â »ý¹°ÇÐÀû µ¥ÀÌÅÍ¿Í µðÁöÅÐ µ¥ÀÌÅÍÀÇ À¶ÇÕÀ» Æ÷ÇÔÇϹǷΠ±â¹Ð Á¤º¸¸¦ º¸È£Çϱâ À§ÇØ °ß°íÇÑ »çÀ̹ö º¸¾È ´ëÃ¥À» È®º¸ÇÏ´Â °ÍÀÌ °¡Àå Áß¿äÇÕ´Ï´Ù. »ý¸í°øÇаú µðÁöÅÐ ±â¼ú ¸ðµÎ¿¡ Àͼ÷ÇÑ ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·Àº ¼ºÀåÀÇ À庮ÀÌ µÇ¾ú½À´Ï´Ù. ÀÌ ±â¼ú °ÝÂ÷´Â ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ¼Ö·ç¼ÇÀÇ °³¹ß°ú µµÀÔÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ¿¬±¸°³¹ß¿¡ ÇÊ¿äÇÑ °í¾×ÀÇ Ãʱâ ÅõÀڴ ƯÈ÷ ½ÅÈï ±â¾÷À̳ª ¼Ò±Ô¸ð ±â¾÷¿¡ ºÎ´ãÀÌ¸ç ½ÃÀå È®´ë¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ±â¾÷

Illumina, Bio-Rad Laboratories, QIAGEN, Sartorius, Thermo Fisher Scientific, Agilent Technologies, Waters Corporation, PerkinElmer, Bruker, Merck KGaA, Danaher, Charles River Laboratories, Lonza Group, Shimadzu Corporation, Tecan Group

¸ñÂ÷

Á¦1Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ Áß¿ä ÀλçÀÌÆ®

Á¦4Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå Àü¸Á

Á¦5Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå Àü·«

Á¦6Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå ±Ô¸ð

Á¦7Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : À¯Çüº°

Á¦8Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : Á¦Ç°º°

Á¦9Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : ±â¼úº°

Á¦11Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : ¿ëµµº°

Á¦12Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : µð¹ÙÀ̽ºº°

Á¦13Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦14Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

Á¦15Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : ±â´Éº°

Á¦16Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : Àü°³º°

Á¦17Àå ÇコÄÉ¾î ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå : Áö¿ªº°

Á¦18Àå °æÀï ±¸µµ

Á¦19Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

CSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Healthcare Bioconvergence Market is anticipated to expand from $145.4 billion in 2024 to $271.4 billion by 2034, growing at a CAGR of approximately 6.4%. The Healthcare Bioconvergence Market encompasses the integration of biology, engineering, and digital technologies to innovate healthcare solutions. This interdisciplinary approach leverages biotechnology, data analytics, and medical devices to enhance diagnostics, treatment, and patient care. As precision medicine and personalized healthcare gain traction, the market is poised for growth, driven by advancements in genomics, artificial intelligence, and wearable technology, fostering novel therapeutic and diagnostic innovations.

The Healthcare Bioconvergence Market is experiencing robust growth, fueled by the integration of biotechnology, information technology, and engineering. The therapeutics segment is the top performer, with biologics and cell therapies driving innovation and offering personalized treatment solutions. Diagnostics follow closely, with advancements in molecular diagnostics and imaging technologies enhancing early disease detection and precision medicine. Within therapeutics, the focus on gene editing and regenerative medicine is expanding, promising transformative impacts on chronic and rare diseases. In diagnostics, the emergence of AI-driven diagnostic tools and wearable health monitoring devices is gaining momentum, facilitating real-time health data analysis and proactive healthcare management. The biomanufacturing sub-segment is also witnessing significant progress, with continuous bioprocessing and 3D bioprinting technologies improving production efficiency and scalability. As healthcare systems increasingly prioritize personalized and preventive care, the bioconvergence market offers lucrative opportunities for innovation, collaboration, and investment, ensuring sustainable growth and improved patient outcomes.

Market Segmentation
TypeTherapeutic, Diagnostic, Preventive, Rehabilitative
ProductBiomaterials, Bioelectronics, Biophotonics, Biosensors, Bioinformatics Tools
ServicesConsulting, Implementation, Support and Maintenance, Managed Services, Training and Education
TechnologyNanotechnology, Genomics, Proteomics, Synthetic Biology, Bioinformatics, Tissue Engineering
ApplicationDrug Discovery, Clinical Trials, Personalized Medicine, Medical Imaging, Regenerative Medicine
DeviceWearable Devices, Implantable Devices, Diagnostic Devices, Monitoring Devices, Therapeutic Devices
End UserHospitals, Research Institutes, Pharmaceutical Companies, Biotechnology Firms, Academic Institutions
ComponentSoftware, Hardware, Platform
FunctionalityData Analysis, Simulation, Modeling, Visualization
DeploymentOn-premise, Cloud-based, Hybrid

Market Snapshot:

The Healthcare Bioconvergence Market is witnessing a dynamic shift in market share, pricing strategies, and new product launches. Companies are increasingly adopting innovative approaches to capture a larger share by introducing cutting-edge technologies that blend biology with engineering. Pricing remains competitive, driven by the influx of new entrants and the continuous evolution of existing technologies. This competitive landscape is further intensified by strategic collaborations and partnerships aimed at enhancing product offerings and expanding market reach. New product launches are frequent, reflecting the rapid pace of technological advancement and the industry's commitment to addressing complex healthcare challenges. Competition benchmarking reveals a diverse array of players, from established pharmaceutical giants to agile biotech startups. These entities are leveraging bioconvergence to gain a competitive edge, focusing on personalized medicine and precision therapeutics. Regulatory influences play a pivotal role, with stringent guidelines shaping the market landscape and ensuring safety and efficacy. The market is characterized by significant R&D investments, particularly in North America and Europe, which are at the forefront of regulatory frameworks and innovation. As the industry evolves, the convergence of healthcare and technology is expected to drive substantial growth, offering lucrative opportunities for stakeholders.

Geographical Overview:

The Healthcare Bioconvergence Market is witnessing remarkable growth across various regions, each presenting unique opportunities. North America stands at the forefront, driven by robust research and development in biotechnology and healthcare. The integration of technology and biology is fostering innovation, with substantial investments from both private and public sectors. This region benefits from a strong ecosystem of startups and established firms. In Europe, the market is gaining momentum due to significant government support and a focus on sustainable healthcare solutions. Countries like Germany and the United Kingdom are leading the charge, emphasizing personalized medicine and advanced diagnostics. The region's commitment to regulatory compliance and ethical standards enhances its market position. Asia Pacific emerges as a dynamic growth pocket, propelled by rapid technological advancements and increasing healthcare demands. China and India are key players, investing heavily in bioconvergence to address healthcare challenges. These countries are leveraging their large populations and technological capabilities to drive market expansion.

Key Trends and Drivers:

The healthcare bioconvergence market is experiencing rapid growth driven by technological advancements and interdisciplinary collaborations. Key trends include the integration of biology with engineering, leading to innovative solutions in diagnostics and therapeutics. The convergence of artificial intelligence and biotechnology is fostering personalized medicine and precision healthcare, enhancing patient outcomes and treatment efficacy. Another significant trend is the rise of bioconvergence startups, which are attracting substantial investments from venture capitalists. These startups are pioneering new approaches to drug discovery and development. Regulatory bodies are increasingly supporting bioconvergence innovations, streamlining approval processes to accelerate market entry. This regulatory support is a crucial driver of market expansion. Additionally, the demand for minimally invasive procedures is propelling the adoption of bioconvergence technologies in surgical applications. Opportunities abound in the development of smart biomaterials and bioelectronics, which are poised to transform traditional healthcare paradigms. Companies that harness these trends and drivers are well-positioned to capitalize on the burgeoning market potential.

Restraints and Challenges:

The Healthcare Bioconvergence Market confronts several pressing restraints and challenges. A predominant issue is the complexity of integrating diverse technologies, which can impede seamless convergence and operational efficiency. This complexity often results in increased costs and extended development timelines, deterring smaller entities from entering the market. Regulatory hurdles further complicate market dynamics, as stringent compliance requirements can delay product approvals and market entry. These regulations, while essential for safety, can stifle innovation and discourage investment. Data privacy concerns present another significant challenge. As bioconvergence involves the amalgamation of biological and digital data, ensuring robust cybersecurity measures is paramount to protect sensitive information. The shortage of skilled professionals adept in both biotechnology and digital technologies poses a barrier to growth. This skills gap can hinder the development and implementation of bioconvergence solutions. Lastly, the high initial investment required for research and development can be prohibitive, particularly for startups and smaller firms, limiting market expansion.

Key Players:

Illumina, Bio-Rad Laboratories, QIAGEN, Sartorius, Thermo Fisher Scientific, Agilent Technologies, Waters Corporation, PerkinElmer, Bruker, Merck KGaA, Danaher, Charles River Laboratories, Lonza Group, Shimadzu Corporation, Tecan Group

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Healthcare Bioconvergence Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Healthcare Bioconvergence Market Outlook

5: Healthcare Bioconvergence Market Strategy

6: Healthcare Bioconvergence Market Size

7: Healthcare Bioconvergence Market, by Type

8: Healthcare Bioconvergence Market, by Product

9: Healthcare Bioconvergence Market, by Services

10: Healthcare Bioconvergence Market, by Technology

11: Healthcare Bioconvergence Market, by Application

12: Healthcare Bioconvergence Market, by Device

13: Healthcare Bioconvergence Market, by End User

14: Healthcare Bioconvergence Market, by Component

15: Healthcare Bioconvergence Market, by Functionality

16: Healthcare Bioconvergence Market, by Deployment

17: Healthcare Bioconvergence Market, by Region

18: Competitive Landscape

19: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â